Newcastle University
Browse

File(s) under embargo

Reason: until the associated manuscript has been published.

1

month(s)

22

day(s)

until file(s) become available

Cystic Fibrosis Target Product Profiles: Focus group data (clinical and people with CF)

dataset
posted on 2024-10-18, 15:41 authored by Nicola HoweNicola Howe, Kile GreenKile Green, Raasti Naseem

Diagnostics are key to the appropriate detection, treatment and management of many conditions and associated health implications. People with cystic fibrosis are susceptible to recurrent pulmonary infections that over time contribute to deterioration and degeneration of the lung. Launched in 2019, the Cystic Fibrosis (CF) Antimicrobial Resistance (AMR) Syndicate was formed to accelerate the translation and adoption of new CF antimicrobials and diagnostics to the clinic through collaboration (https://cfamr.org.uk/), bringing better treatment options to people with CF, faster.

To catalyse the development of new diagnostics, the CF AMR Syndicate, together with the Newcastle NIHR HealthTech Research Centre (formerly Newcastle NIHR MIC), has worked with the wider community to understand the unmet diagnostic needs and develop a suite of Target Product Profiles (TPPs) for CF lung infection diagnostics. The intention of this is to drive diagnostic discovery, focusing efforts where they are needed the most. Although developed in the UK with input from UK based experts and people with CF, we intend for the impact of these TPPs to be global.

This project involved three main phases, sandwiched between planning and management activities, and a dissemination strategy programme, all guided by an expert advisory group.

Phase 1 involved a landscape analysis to identify and prioritise unmet diagnostic needs via multiple focus groups of clinical experts and people with Cystic Fibrosis (pwCF), as well as a scoping review of the diagnostic space and available diagnostic tests (https://doi.org/10.1016/j.resinv.2024.07.005).

Phase 2 involved drafting the TPPs using existing literature and regulatory documentation, focus groups, one-to-one interviews with key opinion leaders (KoLs), and a web-based survey, to define ‘minimal’ and ‘optimal’ characteristics for each TPP.

Phase 3 refined and validated the TPP content through additional interviews, a two-round modified Delphi exercise, and a virtual symposium.

These data are from phase 2 of this study and are the outputs of expert and patient focus groups discussing the CF care pathway, positive and negative aspects of clinical care, unmet needs in CF, and the perspectives of pwCF and clinical teams on optimal and desired characteristics for diagnostic tests in CF.

This patient-centric methodology builds upon the experience and network of MDC and CF Trust in the development of TPPs to guide CF antimicrobial therapeutic development. These early stakeholder focus groups went on to inform all subsequent diagnostic TPP development work, and laid the foundation for subsequent stakeholder elicitation regarding content and focus.

Focus group topic guides are available at: https://doi.org/10.25405/data.ncl.26477263.

The final TPP documents (and a report from the virtual symposium) are available at: https://cfamr.org.uk/therapeutic-tpp/.

Funding

RES/0280/0663

History